TVGN TEVOGEN BIO HOLDINGS INC

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame



WARREN, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- , CEO of (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, congratulates Board Member, PE, CSP, MBA, as he was inducted into The New Jersey League of Municipalities Hall of Fame this month.

Mayor Sordillo was inducted into the Hall of Fame for his dedicated tenure of 24 years of continuous service as a Warren Township Committee Member. As an elected official, Mayor Sordillo served the community by leading the municipal government, providing oversight to the township’s operations, and implementing policies for the public good, essentially working for the benefit of the citizens he represents.

“Mayor Sordillo exemplifies the qualities of a dedicated public servant, making personal sacrifices to answer a call that many shy away from. While policy debates are essential and differing perspectives form the bedrock of democracy, such discussions are incomplete without acknowledging the personal commitments and sacrifices made by leaders like Mayor Sordillo. We extend our deepest gratitude and congratulations on your remarkable service.” said Ryan Saadi, MD, MPH, Tevogen Bio’s Chief Executive Officer.

“It has been an honor to serve the residents of Warren and be part of a very high performing team of committee people. During our tenure, we built a new library, a new town hall, extensive youth facilities including the football complex, playgrounds, and basketball courts; and purchased around 1,000 acres of open space which includes the Wagner Farm. This was accomplished while maintaining a AAA bond rating and having one tenth of the long-term debt allowable by the State of NJ.” said Mayor Sordillo.

Former New Jersey Governor Don DeFrancesco and current State Senator John Bramnick recognized Warren Township and its leadership, both having said that the Township is a model for the State and one of the best places to live. During the Mayor’s term, Warren was voted by Money magazine as the sixth best place to live in America; and again by New Jersey Monthly, as the second-best place to live in Central NJ.

Mayor Sordillo will be honored along with Gary DiNardo, Carolann Garafola, and the late Frank Salvato during an event next week.

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

 

A photo accompanying this announcement is available at



EN
05/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a ...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterp...

 PRESS RELEASE

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisit...

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) --   (“Tevogen Bio Holdings Inc.”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if ...

 PRESS RELEASE

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sc...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) --   (“Tevogen Bio Holdings Inc.”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if consummat...

 PRESS RELEASE

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to ...

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company’s future financial per...

 PRESS RELEASE

Tevogen to Align Long-Term Stock-Based Incentive Program With Company ...

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company’s long term incentives plan. Tevogen Founder and CEO, Dr. Ry...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch